StartupHistory

An open directory of startups through time

Public records · dated sources
Free to read. Free to reuse.

Company records / endocyte.com

Endocyte

Endocyte (endocyte.com): 3 changes recorded in its website history since January 2008. Homepage last checked 5 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

  1. HeadlineBetween and
    BeforeEndocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)
    AfterReimagining medicine, together.

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagecurrent websiteHistorical capture not publicly availableLink to observation
  2. HeadlineBetween and
    BeforeThe future of precision medicine
    AfterEndocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation
  3. HiringBetween and

    Added a careers page.

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation

First recorded website

Observed 4 June 2015

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

How it described itself

The future of precision medicine

Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).

archived pageLink to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

  1. Seen November 2026 · 1 capture · latest observed messagingReimagining medicine, together.

    For more than 250 years–and 30 years as Novartis–we’ve pursued scientific breakthroughs for one purpose: people. Today, we take on the toughest challenges in healthcare and turn innovations into medic

    This wording observed 5 November 2026.

    current websiteHistorical capture not publicly available
  2. July 2018 – September 2019 · 3 capturesEndocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)

    Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).

    This wording observed 17 September 2019.

    archived page
    Inspect 3 captures in this group
    • 1 July 2018 · Endocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) archived page
    • 18 August 2019 · Endocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) archived page
    • 17 September 2019 · Endocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC) archived page
  3. June 2015 – July 2017 · 3 capturesThe future of precision medicine

    Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).

    This wording observed 9 July 2017.

    archived page
    Inspect 3 captures in this group

Cite this record

StartupHistory, “Endocyte” company record, https://startuphistory.org/c/endocyte.com

Machine-readable: /c/endocyte.com.json. How changes are found: method.